It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Actin dynamics control early T-cell receptor (TCR) signalling during T-cell activation. However, the precise regulation of initial actin rearrangements is not completely understood. Here, we have investigated the regulatory role of the phosphatase Slingshot-1 (SSH1) in this process. Our data show that SSH1 rapidly polarises to nascent cognate synaptic contacts and later relocalises to peripheral F-actin networks organised at the mature immunological synapse. Knockdown of SSH1 expression by CRISPR/Cas9-mediated genome editing or small interfering RNA reveal a regulatory role for SSH1 in CD3ε conformational change, allowing Nck binding and proper downstream signalling and immunological synapse organisation. TCR triggering induces SSH1-mediated activation of actin dynamics through a mechanism mediated by Limk-1 inactivation. These data suggest that during early TCR activation, SSH1 is required for rapid F-actin rearrangements that mediate initial conformational changes of the TCR, integrin organisation and proximal signalling events for proper synapse organisation. Therefore, the SSH1 and Limk-1 axis is a key regulatory element for full T cell activation.
This study identifies a role for the phosphatase Slingshot-1 in controlling LIMK1 and PAK1 signalling to achieve the cytoskeletal rearrangements that facilitate NCK recruitment to the T-cell receptor and downstream signaling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT, School of Medicine, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); 12 de Octubre Health Research Institute (imas12), Madrid, Spain (GRID:grid.144756.5) (ISNI:0000 0001 1945 5329); UAM, Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126)
2 Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT, School of Medicine, Madrid, Spain (GRID:grid.4795.f) (ISNI:0000 0001 2157 7667); 12 de Octubre Health Research Institute (imas12), Madrid, Spain (GRID:grid.144756.5) (ISNI:0000 0001 1945 5329)
3 UAM, Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); UAM, Videomicroscopy Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126)
4 Campus de Cantoblanco, Centro de Biología Molecular Severo Ochoa, Madrid, Spain (GRID:grid.465524.4)
5 Centro Nacional de Investigaciones Oncológicas (CNIO), Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Madrid, Spain (GRID:grid.7719.8) (ISNI:0000 0000 8700 1153); Medioambientales y Tecnologicas (CIEMAT); Advanced Therapies Unit, Instituto de Investigacion Sanitaria Fundacion Jiménez Díaz; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185); Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126)
6 Centro Nacional de Investigaciones Oncológicas (CNIO), Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Madrid, Spain (GRID:grid.7719.8) (ISNI:0000 0000 8700 1153)
7 UAM, Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); Fundación Centro Nacional de Investigaciones Cardiovasculares-Carlos III, Area of Vascular Pathophysiology, Laboratory of Intercellular Communication, Madrid, Spain (GRID:grid.467824.b) (ISNI:0000 0001 0125 7682); CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (GRID:grid.510932.c)
8 UAM, Immunology Service, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); UAM, Videomicroscopy Unit, Instituto de Investigación Sanitaria del Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); Fundación Centro Nacional de Investigaciones Cardiovasculares-Carlos III, Area of Vascular Pathophysiology, Laboratory of Intercellular Communication, Madrid, Spain (GRID:grid.467824.b) (ISNI:0000 0001 0125 7682); CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (GRID:grid.510932.c)